Peer-reviewed veterinary case report
Fenofibrate effects on blood fats in dogs with biliary disease
By Gori, Eleonora et al.·Published in Research in veterinary science·2025·Department of Veterinary Sciences, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Pre and post fibrate supplementation lipoprotein electrophoresis in hyperlipemic dogs with biliary tree disease.
- Species:
- dog
Plain-English summary
A group of dogs with chronic biliary disease and high fat levels in their blood were treated with fenofibrate, a medication that helps lower fat levels. After 4 to 6 weeks of treatment, the dogs showed significant improvements, with lower cholesterol and triglyceride levels. The treatment also changed the types of fats in their blood, increasing the good HDL cholesterol and decreasing harmful fats. This suggests that fenofibrate can effectively help manage high fat levels in dogs with biliary issues, potentially reducing liver damage caused by fat buildup.
People also search for: dog high cholesterol treatment · fenofibrate for dogs · biliary disease in dogs symptoms
Abstract
Hyperlipemia is commonly observed in dogs with biliary tree disease, where cholestasis can both cause and result of hyperlipidemia. Fibrate therapy effectively reduce lipemia in dogs with both primary and secondary hyperlipidemia. This study aimed to investigate whether fenofibrate therapy could alter lipoprotein patterns in hyperlipemic cholestatic dogs. Retrospective cohort study on left-over frozen-stored (-80 °C) serum samples of 25 client-owned dogs with chronic biliary disease with hyperlipidemia (hypercholesterolemia and/or hypertriglyceridemia) that underwent fenofibrate therapy at 4-10 mg/kg once daily (T0) and had a re-check after 4-6 weeks (T1). To be included, dogs with hypercholesterolemia (>280 mg/dL) and/or hypertriglyceridemia (>90 mg/dL) had to present a concurrent increase of two or more between alkaline phosphatase (ALP) >250 U/L, gamma-glutamyl transferase (GGT) >11 U/L and total bilirubin >0.3 mg/dL and abdominal ultrasound alterations suggestive for a chronic biliary tree disease. Pre- and post-treatment serum samples were analysed using lipoprotein electrophoresis. Results showed significant reductions in serum cholesterol (median 293 mg/dL vs. 368 mg/dL) and triglycerides (median 70 mg/dL vs. 181 mg/dL). Lipoprotein analysis revealed a significant increase in HDL percentage (from 51 % to 62.9 %) and reductions in VLDL (from 33.2 % to 18 %) and chylomicrons (from 3.2 % to 1.7 %). These results suggest that fenofibrate is effective in reducing lipemia and improving lipid profiles in cholestatic dogs, helping to limit hepatic injury potentially associated with lipid accumulation.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40449137/